Skip to main content
Top
Published in: BMC Primary Care 1/2020

01-12-2020 | Bisphosphonate | Research article

Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice

Authors: Pradnya Naik-Panvelkar, Sarah Norman, Zain Elgebaly, Jeff Elliott, Allan Pollack, Jill Thistlethwaite, Clare Weston, Markus J. Seibel

Published in: BMC Primary Care | Issue 1/2020

Login to get access

Abstract

Background

Among Australians aged 50 and over, an estimated 1 in 4 men and 2 in 5 women will experience a minimal trauma fracture during their remaining lifetime. Effective fracture prevention is hindered by substantial undertreatment, even of patients who clearly warrant pharmacological therapy. Poor adherence to osteoporosis treatment is also a leading cause of repeat fractures and hospitalisation. The aim of this study was to identify current osteoporosis treatment patterns and gaps in practice in Australia, using general practice data, and to explore general practitioners’ (GPs’) attitudes to osteoporosis treatment and their views on patient factors affecting osteoporosis management.

Methods

The study was conducted in two phases. Phase 1 was a longitudinal retrospective cohort study which utilised data from MedicineInsight – a national general practice data program that extracts longitudinal, de-identified patient data from clinical information systems (CISs) of participating general practices. Phase 2 included semi-structured, in-depth telephone interviews with a sample of MedicineInsight practice GPs. Data were analysed using an inductive thematic analysis method informed by the theory of planned behaviour.

Results

A diagnosis of osteoporosis was recorded in 12.4% of patients over the age of 50 years seen in general practice. Of those diagnosed with osteoporosis, almost a quarter were not prescribed osteoporosis medicines. From 2012 to 17, there was a progressive increase in the number of denosumab prescriptions, while prescriptions for bisphosphonates and other osteoporosis medicines decreased. More than 80% of patients who ceased denosumab treatment had no subsequent bisphosphonate prescription recorded. Interviews with GPs revealed beliefs and attitudes that may have influenced their intentions towards prescribing and osteoporosis management.

Conclusions

This study suggests that within the Australian general practice setting, osteoporosis is underdiagnosed and undertreated. In addition, it appears that most patients who ceased denosumab treatment had no record of subsequent antiresorptive therapy, which would place them at risk of further fractures. The study supports the need for the development of clinical education programs addressing GP knowledge gaps and attitudes, and the implementation of specific interventions such as good reminder/recall systems to avoid delays in reviewing and treating patients with osteoporosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Endocrinology Expert Group: Therapeutic Guidelines: Endocrinology: version 5. In. Melbourne, VIC: Therapeutic Guidelines Ltd; 2014. Endocrinology Expert Group: Therapeutic Guidelines: Endocrinology: version 5. In. Melbourne, VIC: Therapeutic Guidelines Ltd; 2014.
2.
go back to reference Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res. 2013;28(11):2317–24.CrossRef Bliuc D, Nguyen ND, Nguyen TV, Eisman JA, Center JR. Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men. J Bone Miner Res. 2013;28(11):2317–24.CrossRef
3.
go back to reference Australian Institute of Health and Welfare: Estimating the prevalence of osteoporosis. In. Canberra, ACT: AIHW; 2014. Australian Institute of Health and Welfare: Estimating the prevalence of osteoporosis. In. Canberra, ACT: AIHW; 2014.
4.
go back to reference Watts JJ, Abimanyi-Ochom J, Sanders KM. Osteoporosis costing all Australians a new burden of disease analysis – 2012 to 2022. In. Osteoporosis Australia: Glebe, NSW; 2017. Watts JJ, Abimanyi-Ochom J, Sanders KM. Osteoporosis costing all Australians a new burden of disease analysis – 2012 to 2022. In. Osteoporosis Australia: Glebe, NSW; 2017.
5.
go back to reference Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008;1:CD001155.
6.
go back to reference Royal Australian College of General Practitioners: Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. In., Second edition edn. Melbourne, VIC: RACGP; 2017. Royal Australian College of General Practitioners: Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age. In., Second edition edn. Melbourne, VIC: RACGP; 2017.
8.
go back to reference Australian Institute of Health and Welfare: Use of antiresorptive agents for osteoporosis management. In. Canberra: Australian Institute of Health and Welfare; 2011: 42. Australian Institute of Health and Welfare: Use of antiresorptive agents for osteoporosis management. In. Canberra: Australian Institute of Health and Welfare; 2011: 42.
9.
go back to reference Major G, Ling R, Searles A, Niddrie F, Kelly A, Holliday E, Attia J, Bogduk N. The costs of confronting osteoporosis: cost study of an Australian fracture liaison service. JBMR Plus. 2019;3(1):56–63.CrossRef Major G, Ling R, Searles A, Niddrie F, Kelly A, Holliday E, Attia J, Bogduk N. The costs of confronting osteoporosis: cost study of an Australian fracture liaison service. JBMR Plus. 2019;3(1):56–63.CrossRef
10.
go back to reference Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2017;32(3):424–30.CrossRef Khosla S, Cauley JA, Compston J, Kiel DP, Rosen C, Saag KG, Shane E. Addressing the crisis in the treatment of osteoporosis: a path forward. J Bone Miner Res. 2017;32(3):424–30.CrossRef
11.
go back to reference Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898–907.CrossRef Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898–907.CrossRef
12.
go back to reference Seibel MJ. No more excuses: fracture liaison services work and are cost-effective. Med J Aust. 2011;195(10):566–7.CrossRef Seibel MJ. No more excuses: fracture liaison services work and are cost-effective. Med J Aust. 2011;195(10):566–7.CrossRef
13.
go back to reference Australian Bureau of Statistics: 4364.0.55.002 - Health Service Usage and Health Related Actions, Australia, 2014–15. In. Canberra, ACT: ABS; 2017. Australian Bureau of Statistics: 4364.0.55.002 - Health Service Usage and Health Related Actions, Australia, 2014–15. In. Canberra, ACT: ABS; 2017.
14.
go back to reference Inderjeeth CA, Inderjeeth AJ, Raymond WD. Medication selection and patient compliance in the clinical management of osteoporosis. Aust Fam Physician. 2016;45(11):814–7.PubMed Inderjeeth CA, Inderjeeth AJ, Raymond WD. Medication selection and patient compliance in the clinical management of osteoporosis. Aust Fam Physician. 2016;45(11):814–7.PubMed
15.
go back to reference Lindsay BR, Olufade T, Bauer J, Babrowicz J, Hahn R. Patient-reported barriers to osteoporosis therapy. Arch Osteoporos. 2016;11:19.CrossRef Lindsay BR, Olufade T, Bauer J, Babrowicz J, Hahn R. Patient-reported barriers to osteoporosis therapy. Arch Osteoporos. 2016;11:19.CrossRef
16.
go back to reference Sambrook P. Compliance with treatment in osteoporosis patients--an ongoing problem. Aust Fam Physician. 2006;35(3):135–7.PubMed Sambrook P. Compliance with treatment in osteoporosis patients--an ongoing problem. Aust Fam Physician. 2006;35(3):135–7.PubMed
17.
go back to reference Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after Denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291–6.CrossRef Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after Denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291–6.CrossRef
18.
go back to reference Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. Curr Osteoporos Rep. 2019;17(1):8–15.CrossRef Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. Curr Osteoporos Rep. 2019;17(1):8–15.CrossRef
19.
go back to reference NPS MedicineWise: General practice insights report July 2016–June 2017: a working paper. In. Sydney, NSW: NPS MedicineWise; 2018. NPS MedicineWise: General practice insights report July 2016–June 2017: a working paper. In. Sydney, NSW: NPS MedicineWise; 2018.
20.
go back to reference NPS MedicineWise: MedicineInsight data book version 2.1. In. Sydney, NSW: NPS MedicineWise; October 2018. NPS MedicineWise: MedicineInsight data book version 2.1. In. Sydney, NSW: NPS MedicineWise; October 2018.
21.
go back to reference Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychology. 2006;3:77–101.CrossRef Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychology. 2006;3:77–101.CrossRef
22.
go back to reference Ajzen I. The theory of planned behaviour. Organ Behav Hum Decis Process. 1991;50(2):179–211.CrossRef Ajzen I. The theory of planned behaviour. Organ Behav Hum Decis Process. 1991;50(2):179–211.CrossRef
23.
go back to reference Tsiantou V, Shea S, Martinez L, Agius D, Basak O, Faresjo T, Moschandreas J, Samoutis G, Symvoulakis EK, Lionis C. Eliciting general practitioners' salient beliefs towards prescribing: a qualitative study based on the theory of planned behaviour in Greece. J Clin Pharm Ther. 2013;38(2):109–14.CrossRef Tsiantou V, Shea S, Martinez L, Agius D, Basak O, Faresjo T, Moschandreas J, Samoutis G, Symvoulakis EK, Lionis C. Eliciting general practitioners' salient beliefs towards prescribing: a qualitative study based on the theory of planned behaviour in Greece. J Clin Pharm Ther. 2013;38(2):109–14.CrossRef
24.
go back to reference Guenette L, Lauzier S, Guillaumie L, Giguere G, Gregoire JP, Moisan J. Patients' beliefs about adherence to oral antidiabetic treatment: a qualitative study. Patient Prefer Adherence. 2015;9:413–20.CrossRef Guenette L, Lauzier S, Guillaumie L, Giguere G, Gregoire JP, Moisan J. Patients' beliefs about adherence to oral antidiabetic treatment: a qualitative study. Patient Prefer Adherence. 2015;9:413–20.CrossRef
25.
go back to reference Henry MJ, Pasco JA, Nicholson GC, Kotowicz MA. Prevalence of osteoporosis in Australian men and women: Geelong osteoporosis study. Med J Aust. 2011;195(6):321–2.CrossRef Henry MJ, Pasco JA, Nicholson GC, Kotowicz MA. Prevalence of osteoporosis in Australian men and women: Geelong osteoporosis study. Med J Aust. 2011;195(6):321–2.CrossRef
26.
go back to reference Elliott-Rudder M, Harding C, McGirr J, Seal A, Pilotto L. Using electronic medical records to assess the rate of treatment for osteoporosis in Australia. Aust Fam Physician. 2017;46(7):508–12.PubMed Elliott-Rudder M, Harding C, McGirr J, Seal A, Pilotto L. Using electronic medical records to assess the rate of treatment for osteoporosis in Australia. Aust Fam Physician. 2017;46(7):508–12.PubMed
27.
go back to reference Alami S, Hervouet L, Poiraudeau S, Briot K, Roux C. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of Patients' and Practitioners' views. PLoS One. 2016;11(6):e0158365.CrossRef Alami S, Hervouet L, Poiraudeau S, Briot K, Roux C. Barriers to effective postmenopausal osteoporosis treatment: a qualitative study of Patients' and Practitioners' views. PLoS One. 2016;11(6):e0158365.CrossRef
28.
go back to reference Parker D. An audit of osteoporotic patients in an Australian general practice. Aust Fam Physician. 2013;42(6):423–7.PubMed Parker D. An audit of osteoporotic patients in an Australian general practice. Aust Fam Physician. 2013;42(6):423–7.PubMed
29.
go back to reference Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare study. J Bone Miner Res. 2004;19(12):1969–75.CrossRef Eisman J, Clapham S, Kehoe L. Osteoporosis prevalence and levels of treatment in primary care: the Australian BoneCare study. J Bone Miner Res. 2004;19(12):1969–75.CrossRef
30.
go back to reference Chen JS, Hogan C, Lyubomirsky G, Sambrook PN. Management of osteoporosis in primary care in Australia. Osteoporos Int. 2009;20(3):491–6.CrossRef Chen JS, Hogan C, Lyubomirsky G, Sambrook PN. Management of osteoporosis in primary care in Australia. Osteoporos Int. 2009;20(3):491–6.CrossRef
31.
go back to reference Mendis AS, Ganda K, Seibel MJ. Barriers to secondary fracture prevention in primary care. Osteoporos Int. 2017;28(10):2913–9.CrossRef Mendis AS, Ganda K, Seibel MJ. Barriers to secondary fracture prevention in primary care. Osteoporos Int. 2017;28(10):2913–9.CrossRef
32.
go back to reference Morizio P, Burkhart JI, Ozawa S. Denosumab: a unique perspective on adherence and cost-effectiveness compared with Oral bisphosphonates in osteoporosis patients. Ann Pharmacother. 2018;52(10):1031–41.CrossRef Morizio P, Burkhart JI, Ozawa S. Denosumab: a unique perspective on adherence and cost-effectiveness compared with Oral bisphosphonates in osteoporosis patients. Ann Pharmacother. 2018;52(10):1031–41.CrossRef
33.
go back to reference Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL. Final results of the DAPS (Denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317–26.CrossRef Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL. Final results of the DAPS (Denosumab adherence preference satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317–26.CrossRef
34.
go back to reference Australian Medicines Handbook. Adelaide, SA: AMH Pty Ltd; 2018. Australian Medicines Handbook. Adelaide, SA: AMH Pty Ltd; 2018.
35.
go back to reference Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Torring O, Valter I, Wang AT, et al. Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–8.CrossRef Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, Roux C, Torring O, Valter I, Wang AT, et al. Vertebral fractures after discontinuation of Denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190–8.CrossRef
36.
go back to reference McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28(5):1723–32.CrossRef McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28(5):1723–32.CrossRef
37.
go back to reference Usherwood T. Encouraging adherence to long-term medication. Aust Prescr. 2017;40(4):147–50.CrossRef Usherwood T. Encouraging adherence to long-term medication. Aust Prescr. 2017;40(4):147–50.CrossRef
38.
go back to reference Tobin L, de Almedia Neto AC, Wutzke S, Patterson C, Mackson J, Weekes L, Williamson M. Influences on the prescribing of new drugs. Aust Fam Physician. 2008;37(1–2):78–80 3.PubMed Tobin L, de Almedia Neto AC, Wutzke S, Patterson C, Mackson J, Weekes L, Williamson M. Influences on the prescribing of new drugs. Aust Fam Physician. 2008;37(1–2):78–80 3.PubMed
Metadata
Title
Osteoporosis management in Australian general practice: an analysis of current osteoporosis treatment patterns and gaps in practice
Authors
Pradnya Naik-Panvelkar
Sarah Norman
Zain Elgebaly
Jeff Elliott
Allan Pollack
Jill Thistlethwaite
Clare Weston
Markus J. Seibel
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Primary Care / Issue 1/2020
Electronic ISSN: 2731-4553
DOI
https://doi.org/10.1186/s12875-020-01103-2

Other articles of this Issue 1/2020

BMC Primary Care 1/2020 Go to the issue